Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways.

Wang C, Delogu S, Ho C, Lee SA, Gui B, Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, Calvisi DF, Chen X.

J Hepatol. 2012 Sep;57(3):577-83. doi: 10.1016/j.jhep.2012.04.026. Epub 2012 May 19.

2.

Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis.

Lee SA, Ladu S, Evert M, Dombrowski F, De Murtas V, Chen X, Calvisi DF.

Hepatology. 2010 Aug;52(2):506-17. doi: 10.1002/hep.23681.

3.

Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.

Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR.

Cancer Res. 2006 Feb 15;66(4):2048-58.

4.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer.

Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X.

Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

PMID:
18214995
5.

Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.

Li L, Pilo GM, Li X, Cigliano A, Latte G, Che L, Joseph C, Mela M, Wang C, Jiang L, Ribback S, Simile MM, Pascale RM, Dombrowski F, Evert M, Semenkovich CF, Chen X, Calvisi DF.

J Hepatol. 2016 Feb;64(2):333-341. doi: 10.1016/j.jhep.2015.10.004. Epub 2015 Oct 22.

6.

SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.

Delogu S, Wang C, Cigliano A, Utpatel K, Sini M, Longerich T, Waldburger N, Breuhahn K, Jiang L, Ribback S, Dombrowski F, Evert M, Chen X, Calvisi DF.

Oncotarget. 2015 Feb 10;6(4):2222-34.

7.

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.

Hu J, Che L, Li L, Pilo MG, Cigliano A, Ribback S, Li X, Latte G, Mela M, Evert M, Dombrowski F, Zheng G, Chen X, Calvisi DF.

Sci Rep. 2016 Feb 9;6:20484. doi: 10.1038/srep20484.

8.

Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, Destefanis G, Delogu S, Zimmermann A, Ericsson J, Brozzetti S, Staniscia T, Chen X, Dombrowski F, Evert M.

Gastroenterology. 2011 Mar;140(3):1071-83. doi: 10.1053/j.gastro.2010.12.006. Epub 2010 Dec 11.

9.

SCD1 Expression is dispensable for hepatocarcinogenesis induced by AKT and Ras oncogenes in mice.

Li L, Wang C, Calvisi DF, Evert M, Pilo MG, Jiang L, Yuneva M, Chen X.

PLoS One. 2013 Sep 19;8(9):e75104. doi: 10.1371/journal.pone.0075104. eCollection 2013.

10.

V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.

Evert M, Calvisi DF, Evert K, De Murtas V, Gasparetti G, Mattu S, Destefanis G, Ladu S, Zimmermann A, Delogu S, Thiel S, Thiele A, Ribback S, Dombrowski F.

Hepatology. 2012 May;55(5):1473-84. doi: 10.1002/hep.25600. Epub 2012 Apr 4.

PMID:
22271091
11.

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.

Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X, Calvisi DF.

Cell Cycle. 2013 Jul 1;12(13):1999-2010. doi: 10.4161/cc.25099. Epub 2013 Jun 6.

12.

Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.

Wong CC, Au SL, Tse AP, Xu IM, Lai RK, Chiu DK, Wei LL, Fan DN, Tsang FH, Lo RC, Wong CM, Ng IO.

PLoS One. 2014 Dec 26;9(12):e115036. doi: 10.1371/journal.pone.0115036. eCollection 2014.

13.

Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.

Chen YL, Song JJ, Chen XC, Xu W, Zhi Q, Liu YP, Xu HZ, Pan JS, Ren JL, Guleng B.

World J Gastroenterol. 2015 Aug 14;21(30):9093-102. doi: 10.3748/wjg.v21.i30.9093.

14.

AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, Dombrowski F, Evert M, Chen X, Calvisi DF.

Hepatology. 2012 Mar;55(3):833-45. doi: 10.1002/hep.24736. Epub 2011 Dec 19.

15.

Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.

Tao J, Ji J, Li X, Ding N, Wu H, Liu Y, Wang XW, Calvisi DF, Song G, Chen X.

Oncotarget. 2015 Mar 30;6(9):6977-88.

16.

Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.

Xin B, Yamamoto M, Fujii K, Ooshio T, Chen X, Okada Y, Watanabe K, Miyokawa N, Furukawa H, Nishikawa Y.

Oncogene. 2017 Sep 7;36(36):5087-5097. doi: 10.1038/onc.2017.114. Epub 2017 May 8.

17.

PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.

Liu WR, Tian MX, Yang LX, Lin YL, Jin L, Ding ZB, Shen YH, Peng YF, Gao DM, Zhou J, Qiu SJ, Dai Z, He R, Fan J, Shi YH.

Oncotarget. 2015 Jan 20;6(2):846-61.

18.

Staphylococcal Nuclease and Tudor Domain Containing 1 (SND1 Protein) Promotes Hepatocarcinogenesis by Inhibiting Monoglyceride Lipase (MGLL).

Rajasekaran D, Jariwala N, Mendoza RG, Robertson CL, Akiel MA, Dozmorov M, Fisher PB, Sarkar D.

J Biol Chem. 2016 May 13;291(20):10736-46. doi: 10.1074/jbc.M116.715359. Epub 2016 Mar 20.

19.

The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.

Chiu CY, Kuo KK, Kuo TL, Lee KT, Cheng KH.

Mol Cancer Res. 2012 Mar;10(3):415-27. doi: 10.1158/1541-7786.MCR-11-0293. Epub 2012 Jan 12.

20.

Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.

Yu HC, Chen HJ, Chang YL, Liu CY, Shiau CW, Cheng AL, Chen KF.

Biochem Pharmacol. 2013 Feb 1;85(3):356-66. doi: 10.1016/j.bcp.2012.11.009. Epub 2012 Nov 23.

PMID:
23178652

Supplemental Content

Support Center